



Proportion of Cytotoxic Peripheral Blood Natural Killer Cells and T-Cell Large Granular Lymphocytes in Recurrent Miscarriage and Repeated Implantation Failure: Case–Control Study and Meta-analysis

Kamila Kolanska¹ · Ludovic Suner² · Jonathan Cohen¹ · Yasmine Ben Kraiem¹ · Leo Placais³ · Olivier Fain³ · Marie Bornes¹ · Lise Selleret¹ · François Delhommeau² · Frédéric Feger² · Emmanuelle Mathieu d'Argent¹ · Emile Darai¹ · Nathalie Chabbert-Buffet¹ · Jean-Marie Antoine¹ · Gilles Kayem⁵ · Arsène Mekinian^{3,4} 

Received: 22 November 2018 / Accepted: 11 May 2019 / Published online: 30 May 2019
© L. Hirsfeld Institute of Immunology and Experimental Therapy, Wrocław, Poland 2019

Abstract

We aimed to compare the proportion of peripheral blood natural killer (NK) cells (CD3⁻CD56⁺) and T-cell large granular lymphocytes (CD8⁺CD57⁺) during preconception in a homogenous group of women with unexplained well-defined recurrent miscarriage (RM) and repeated implantation failure (RIF) vs healthy controls in relation to pregnancy outcomes. This case–control study followed by a literature review and meta-analysis was conducted in three university hospitals. Patients and controls were consecutively recruited from December 2015 to October 2017. In total, 115 women were included in the study: 54 with RM, 41 with RIF and 20 healthy controls with ≥ 2 term births. Percentages of CD3⁻CD56⁺ and CD8⁺CD57⁺ cells and sub-populations of CD3⁻CD56⁺ cells did not differ between cases and controls. The results for women with subsequent miscarriage did not differ from those with live births. The meta-analysis of the literature showed higher NK-cell proportions in RM [mean difference 3.47 (95% CI 2.94–4.00); $p < 0.001$] and RIF [mean difference 1.64 (95% CI 0.82–2.45); $p < 0.001$] than controls. However, the heterogeneity between the different studies was high. The proportion of peripheral blood CD3⁻CD56⁺ and CD8⁺CD57⁺ cells in the preconception period does not reflect the risk of implantation failure or miscarriage and should not be recommended indicators for the management of RM and RIF. Further prospective large studies are needed to develop a reliable peripheral blood marker of immune deregulation.

Keywords Natural killer cells · NK · T-cell large granular lymphocytes · T-LGL · Recurrent miscarriage · Recurrent implantation failure · RIF · Pregnancy outcome

✉ Arsène Mekinian
arsene.mekinian@aphp.fr

- ¹ Service de Gynécologie Obstétrique et Médecine de la Reproduction, Hôpital Tenon, AP-HP, Faculté de Médecine Sorbonne Université, 4 rue de la Chine, 75020 Paris, France
- ² Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine CRSA, APHP, Hôpital Saint-Antoine, Paris, France
- ³ Sorbonne Universités, UPMC Université Paris 06, UMR 7211, Service de Médecine Interne, Département Hospitalo-Universitaire Inflammation-Immunopathologie-Biothérapie (DHU i2B), 75005 Paris, France
- ⁴ AP-HP, Hôpital Saint Antoine, Service de Médecine Interne et Inflammation-Immunopathologie-Biothérapie Department (DHU i2B), Faculté de Médecine Sorbonne Université, 184 rue du Faubourg Saint Antoine, 75012 Paris, France
- ⁵ Service de Gynécologie Obstétrique, Hôpital Armand-Trousseau, 26, avenue du Docteur-Arnold-Netter, 75012 Paris, France

Introduction

Human reproduction is a complex process, and a certain proportion of early pregnancies fail to continue (Shepard and Fantel 1979). Most embryonic and foetal losses are observed at the per-implantation period and are sporadic, but some women experience repeated early pregnancy failures. Recurrent miscarriage (RM) is defined as a history of at least three consecutive spontaneous miscarriages before 12 weeks of gestation and occurs in about 1–3% of women (Mekinian et al. 2016). Recurrent implantation failure (RIF) is defined as the absence of pregnancy after at least three transfers of good-quality embryos after in vitro fecundation/intracytoplasmic sperm injection (IVF/ICSI) (Thornhill et al. 2005) and is observed in about 50% of couples undergoing assisted reproductive technology.

More than 50% of RM and RIF cases remain unexplained (i.e., without precise aetiologies after extensive exploration), and recent data showed an altered proportion of endometrial immune cells in the preconception period in up to 82% of cases (Chen et al. 2017; Lédée et al. 2016). Excessive activation of uterine natural killer (uNK) cells and T-helper 1 cell profile consistent with an inflammatory cytotoxic endometrial profile could affect the embryo–endometrium interaction and trophoblastic invasion during early pregnancy, and cause RM and RIF (Chen et al. 2017; Lédée et al. 2016). Nevertheless, endometrial cell analysis is still difficult in routine screening and the preconception data could be less valuable at the time of the pregnancy. Even though endometrial and blood lymphocytes seem different in their phenotypes and functions (Manaster and Mandelboim 2008; Moffett-King 2002), less invasive tools guiding the management of RM and RIF are needed.

Several studies have suggested increased numbers of peripheral blood NK cells in women with RM (King et al. 2010; Ntrivalas et al. 2005; Seshadri and Sunkara 2014; Shakhar et al. 2003), with less consensual data in RIF (Fukui et al. 2008; Ntrivalas et al. 2005; Sacks et al. 2012). However, the design of those studies was heterogeneous, with various definitions of RIF and RM. Several studies included only two, early, or not-consecutive miscarriages, and other aetiologies of RM and RIF were not always excluded. Various definitions of peripheral blood NK cells were considered in these studies, such as CD56⁺, CD16⁺ or CD56⁺CD16⁺ cells. In a recent meta-analysis, NK cells were evaluated in women with infertility, with conflictual data considering absolute numbers or percentages (Seshadri and Sunkara 2014). The population of lymphocytes strongly represented in the human endometrium and mostly affected by hormonal fluctuations is represented by uNK cells (Wira et al. 2015), but other immune cells also seem involved in endometrial maturation, embryo implantation and placentation. Among them, T lymphocytes represent about 40–50% of endometrial immune cells, and a decrease in number of CD8⁺ T lymphocytes as well as altered activation status have been described in women with RM (Southcombe et al. 2017; Wira et al. 2015).

T-cell large granular lymphocytes (T-LGLs) are defined as post-thymic antigen-primed, constitutively activated CD3⁺CD8⁺ T lymphocytes characterised by the presence of cytotoxic granulations in their cytoplasm and the co-expression of CD57 (CD3⁺CD8⁺CD57⁺) (Lamy et al. 2017; Zhang et al. 2016). CD57⁺ expression is connected to the persistent immune stimulation of T cells, may result from multiple cell divisions and may predict replicative senescence of CD8⁺ T cells (Strioga et al. 2011). Their presence can be detected after hematopoietic stem-cell, bone-marrow or solid-organ transplantation (Gill et al. 2012; Matsuda et al. 2017; Mohty et al. 2002), but their accumulation can

be physiologically observed in healthy individuals and is associated with natural ageing (Strioga et al. 2011). Chronic viral infection (principally cytomegalovirus and HIV), acute physical stress, autoimmune diseases, chronic pulmonary disease, cancer, graft-versus-host disease, chronic alcoholism or immunosuppression has been proposed as possible mechanisms of their expansion (Dolstra et al. 1995; Mohty et al. 2001; Strioga et al. 2011). Their function and pathogenesis are not fully elucidated, but they seem to exert a suppressive effect on polyclonal T-cell activation and cytotoxic activity, B-cell differentiation and immunoglobulin production (Wang et al. 1994). Yet, the implication of T-LGLs in the pregnancy implantation process and in women with RM and RIF has not been analysed.

We aimed to compare the proportion of peripheral blood NK cells and T-LGLs in the preconception period in a homogenous group of women with unexplained, well-defined RM and RIF vs healthy controls and in relation to pregnancy outcomes. These data were supplemented with a systematic literature review and meta-analysis of all available studies of blood NK cells.

Patients and Methods

Participants

This case–control study followed by literature review and meta-analysis was conducted with the collaboration of the Department of Internal Medicine of Saint-Antoine Hospital (Paris), the Department of Gynaecology, Obstetrics and Reproductive Medicine of Tenon Hospital (Paris) and the Department of Gynaecology and Obstetrics of Trousseau Hospital (Paris). Patients and controls were consecutively recruited from December 2015 to October 2017.

The study groups consisted of 54 women with at least three consecutive miscarriages (RM) and 41 women with failure of at least three transfers of good quality embryos (RIF). We included 20 fertile women with a history of ≥ 2 term births without any obstetrical or maternal adverse event allowing for a normal term birth from Tenon and Saint Antoine hospitals as controls.

All patients and controls gave informed consent before enrolment and the study protocol was approved by the local ethics committee.

Clinical data collected in the preconception period were age, number of pregnancies, number of consecutive miscarriages, number of IVF/ICSI and embryo transfers, body mass index, tobacco and alcohol use, prior medical and surgical history, and medications during each pregnancy.

All patients were non-pregnant women aged 18–45 years with regular menstrual cycles without any immunomodulatory treatment and without aetiology found on usual




Fig. 1 Representative gating strategy used to select NK cells. The total leukocytes were selected using gating weak Side Scatter (SS) and CD45⁺ positivity. Among the CD3⁺CD7⁺ cells, CD56⁺ cells

were defined as total NK cells. Two sub-populations of CD56⁺ NK cells were classified with CD56 and CD16 (CD56^{bright}CD16⁻ and CD56^{dim}CD16⁺) and CD57 expression

screening for RM and RIF: parental karyotypes, electrophoresis of haemoglobin, fasting blood glucose, complete blood count, anti-Müllerian hormone level, thyroid-stimulating hormone level, homocysteine level, 1-25-OH vitamin D level, comprehensive thrombophilia screening (protein-S, protein-C, anti-thrombin III, activated protein-C resistance, prothrombin gene mutation, factor V Leiden positivity, anti-phospholipid antibodies), autoimmune tests (antinuclear, anti-dsDNA, anti-extractable nuclear antigen, and anti-thyroid [anti-thyroperoxidase and anti-thyroglobulin] antibodies), anti-transglutaminase antibodies and anatomical tests (hysteroscopy and/or pelvis ultrasonography). Women with autoimmune thyroiditis ($n=6$) were included in case of pregnancy failure despite normalised thyroid-stimulating hormone level and substitutive thyroid hormone levels during the previous pregnancy.

Flow Cytometry of Peripheral Blood NK Cells and T-LGLs

Surface and cytoplasmic marker analyses of peripheral blood samples were performed within 4 h of collection using fluorescence-activated cell sorting (FACS) according to the manufacturer's recommendation. For the surface markers, the suspension was incubated with antibodies for CD3-AA750, CD8-AA700, CD16-ECD, CD45-KRO, CD56-PC5.5,

CD57-FITC and CD7-PC7 (Beckman Coulter) for 15 min in the dark. Flow cytometry involved use of the Navios cytometer with Kaluza software (both Beckman Coulter). NK cells were defined as CD3⁺CD7⁺CD56⁺. CD56 intensity and CD16 expression allowed for distinguishing immature CD3⁺CD56^{bright}CD16⁻ and mature CD3⁺CD56^{dim}CD16⁺ NK cells. CD57 was evaluated in the CD3⁺CD56^{dim}CD16⁺ subset to define the activation state of mature NK cells (Fig. 1). T-LGLs were defined as CD3⁺CD8⁺CD57⁺ (Fig. 2).

Literature Review and Meta-analysis

Search Strategy

Two investigators (KK and AM) searched MEDLINE via PubMed, Web of Science, congress programs and the Cochrane Library for English-language articles published up to January 2018 by assessing the following keywords in the title and abstract: early RMs, unexplained miscarriages, miscarriages, RMs, recurrent pregnancy loss, IVE, in vitro fertilisation, fertilisation-in vitro, intracytoplasmic sperm injection, sperm injection intracytoplasmic, assisted reproductive techniques, embryo transfer and embryo implantation, NK cells. All articles with sufficient data were included in the literature review.




Fig. 2 Representative gating strategy used to characterise T-LGLs. The total leukocytes were selected by gating weak Side Scatter (SS) and CD45⁺. Among the total lymphocytes, CD3⁺CD8⁺ cells were selected and CD8⁺CD57⁺ lymphocytes were defined as T-LGLs

Study Selection for the Meta-analysis

We included articles describing cases with (1) RM, (2) infertility, (3) age > 18 years, (4) a control group of healthy women, and (5) results of peripheral NK analysis expressed in percentages with mean and SD. Exclusion criteria were lack of sufficient data and evaluating NK-cell proportion during pregnancy. Inclusion and exclusion criteria for the meta-analysis were checked independently for each article by two reviewers (KK and AM). In cases of disagreement, articles were re-examined and discussed until consensus was achieved.

Statistical Analysis

Data are described with frequencies (%) for categorical variables and median (range) for continuous variables. Fisher's exact test was used to compare qualitative variables and the non-parametric Mann–Whitney/Wilcoxon or Kruskal–Wallis test for continuous variables. $P < 0.05$ was considered statistically significant. Statistical analyses involved use of GraphPad Prism v7.0 (GraphPad Software, San Diego, CA, USA).

The meta-analysis was performed according to the recommendations of the Cochrane Collaboration (Bero and Rennie 1995). Relative risks from individual studies were meta-analysed with fixed-effects and random-effects models as appropriate. The prevalence of NK cells in the different groups was analysed by the standardised mean difference.

Heterogeneity of the exposure effects was evaluated graphically with forest plots and statistically with the I^2 test to quantify heterogeneity across studies. We explored the causes of heterogeneity by population features, exposure and study quality. Because of the differences in NK nomenclature, sub-analyses were performed according to sub-populations (i.e., CD56⁺/CD16⁺/CD56⁺CD16⁺, CD56⁺CD16⁺, CD56^{dim}CD16⁺, or CD56^{bright}) in women with RM, infertility and healthy controls. Meta-analysis involved use of Review Manager (RevMan) v5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, 2014).

Results

Population Characteristics

From December 2015 and October 2017, 95 women were included: 54 with RM and 41 with RIF (Table 1). The median age of women was 36.3 years (range 25.0–45.2). In the control group of 20 women with a history of a median of two term live births (range 2–3) the median age was 36.0 years (32.0–43.0).

In total, 12 women (13%) had anti-Müllerian hormone level < 1.1 ng/ml: 3 had basal antral follicular count ≥ 5 and 5 had undergone IVF treatment for infertility. Eight women (8%) had an autoimmune disease, namely thyroiditis ($n = 4$), psoriasis ($n = 1$), rheumatoid polyarthritis ($n = 1$), coeliac disease ($n = 1$) and Crohn disease ($n = 1$);

Table 1 Characteristics of women with RM and RIF

	RM <i>n</i> = 54	RIF <i>n</i> = 41
Clinical characteristics		
Age (years), median (range)	36.3 (25.0–43.2)	36.3 (27.9–45.2)
Obesity (BMI > 30 kg/m ²), <i>n</i> (%)	8 (15)	6 (14)
Autoimmune disease, <i>n</i> (%)	4 (7)	6 (14)
Thyroiditis, <i>n</i> (%)	2 (4)	4 (10)
Endometriosis, <i>n</i> (%)	1 (2)	4 (10)
Obstetric history, median (range)		
No. of pregnancies	6.0 (3.0–16.0)	0.0 (0.0–7.0)
No. of live births	1.0 (0.0–3.0)	0.0 (0.0–1.0)
No. of embryos transferred	0.0 (0.0–2.0)	7.0 (3.0–17.0)
No. of spontaneous miscarriages	5.0 (3.0–15.0)	0.0 (0.0–3.0)
Laboratory data		
AMH level (ng/ml), median (range)	2.2 (0.1–7.8)	2.4 (0.001–9.8)
TSH titres (mUI/l), median (range)	1.8 (0.7–6.9)	2.0 (0.4–5.0)
1,25-OH vitamin D level (pg/ml), median (range)	45.2 (9.0–106.8)	36.7 (22.6–98.4)
C protein activity (%), median (range)	106.0 (68.0–205.0)	106.0 (76.0–133.0)
S protein activity (%), median (range)	87.0 (62.0–119.0)	89.0 (56.0–112.0)
Antithrombin III activity (%), median (range)	102.0 (80.0–130.0)	103.0 (74.0–118.0)
ANA level > 160 ^e , <i>n</i> (%)	10 (18)	11 (27)
Gamma globulin level (g/l), median (range)	12.0 (7.0–19.1)	12.2 (6.6–16.3)
CH50 activity (%), median (range)	72.0 (14.0–133.0)	65.0 (18.0–100.0)
Anti-TPO antibody positivity, <i>n</i> (%)	2 (4)	7 (17)
Anti-TG antibody positivity, <i>n</i> (%)	1 (2)	3 (7)

Results are shown as number (%) or median (range)

BMI body mass index, *AMH* anti-Müllerian hormone, *TSH* thyroid-stimulating hormone, *1,25-OH vitamin D* 1,25-dihydroxy-vitamin D, *ANA* antinuclear antibodies, *CH50* total haemolytic complement, *anti-TPO* anti-thyroid peroxidase, *anti-TG* anti-thyroid globulin, *RM* recurrent miscarriage, *RIF* repeated implantation failure

21 (23%) were positive for antinuclear antibodies [median level 1/160e (range 1/160–1/1280)], in 6% associated with the anti-thyroid antibodies and autoimmune thyroiditis and without any clinical signs, with antinuclear antibody specificity or associated antibodies suggestive of an autoimmune disease in the remaining cases.

The median number of pregnancies and live births was higher for women with RM than RIF [6.0 (3.0–16.0) vs 0.0 (0.0–7.0); $p < 0.0001$ and 1.0 (0.0–3.0) vs 0.0 (0.0–1.0); $p = 0.0001$] (Table 1). History of endometriosis was more frequent for women with RIF than RM [4 (10%) vs 1 (2%); $p = 0.05$], as was the incidence of anti-thyroid peroxidase antibodies [7 (17%) vs 2 (4%); $p = 0.004$].

The time interval after last abortion or implantation failure and the blood analysis was 9 months (1–36) and 5 months (2–26) in the RM and the RIF groups, respectively. A subsequent pregnancy appeared 2 months (0–6) after the blood analysis in 31 women in the RM group. In the RIF group, 15 women have had a subsequent embryo transfer in the 6 months (1–6).

Blood NK Cells

The median proportion of total CD3⁺CD56⁺ NK cells did not differ between women with RM or RIF and healthy controls [9.4% (2.5–31.6), 9.4% (4.3–29.3) and 10.6% (3.4–20.2); $p = 0.43$, respectively], nor did the median proportion of immature CD3⁺CD56^{bright}CD16[−] NK cells differ [6.7% (0.0–19.6), 8.1% (0.0–23.0) and 5.8% (2.0–18.9); $p = 0.18$]. Similarly, the median proportion of mature CD3⁺CD56^{dim}CD16⁺ NK cells did not differ among groups [93.3% (80.4–100.0), 91.9% (77.0–100.0) and 94.3% (81.1–98.0), $p = 0.18$], nor did the median proportion of CD3⁺CD56^{dim}CD16⁺CD57⁺ activated NK cells differ [48.6% (17.7–85.0), 49.6% (18.2–80.9) and 45.2% (28.2–77.2); $p = 0.75$].

For women with RM, 31/54 had a subsequent pregnancy within the 6 months after NK cell analysis: 12 had a RM and 19 a live birth. The median proportion of CD3⁺CD56⁺ NK cells did not differ between the miscarriage and live-birth groups [9.8% (3.2–31.6) vs 9.4% (4.1–15.6); $p = 0.7$]. Similarly, the median proportion of NK

sub-populations—immature CD3⁻CD56^{bright}CD16⁻, mature CD3⁻CD56^{dim}CD16⁺ and CD3⁻CD56^{dim}CD16⁺CD57⁺ activated NK cells—did not differ between the two groups. The number of patients under steroids or intralipid infusions for the subsequent pregnancy did not differ between the two groups (data not shown).

For women with RIF, 28/41 had subsequent embryo transfers within 6 months after NK cell analysis; 15 women became pregnant: 4 had a miscarriage and 11 a live birth. The median proportion of CD3⁻CD56⁺ NK cells did not differ between women who conceived and did not conceive [7.8% (5.2–26.6) vs 9.6% (4.4–18.8); $p = 0.39$], nor did the median proportion of NK sub-populations—immature CD3⁻CD56^{bright}CD16⁻, mature CD3⁻CD56^{dim}CD16⁺ and CD3⁻CD56^{dim}CD16⁺CD57⁺ activated NK cells—differ. The median proportion of CD3⁻CD56⁺ NK cells did not differ between women who had a miscarriage and a live birth [10.9% (5.7–26.6) vs 7.8% (5.2–15.1); $p = 0.34$], nor did the median proportion of NK sub-populations—immature CD3⁻CD56^{bright}CD16⁻, mature CD3⁻CD56^{dim}CD16⁺ and CD3⁻CD56^{dim}CD16⁺CD57⁺ activated NK cells—differ.

Blood T-LGL Lymphocytes

The median proportion of CD3⁺CD8⁺CD57⁺ (T-LGL) lymphocytes did not differ between women with RM or RIF and healthy controls [5.4% (0.4–14.4) and 4.3% (0.0–18.4) vs 3.8% (0.3–9.7); $p = 0.22$] (Table 2). However, the median proportion of CD3⁺CD8⁺CD57⁺ was < 10% for all healthy controls but ≥ 10% for 11 women with RM (20%) and 4 women with RIF (10%) ($p = 0.03$ and $p = 0.3$ for RM women and RIF women vs healthy controls).

For women with RM, the median proportion of CD3⁺CD8⁺CD57⁺ cells did not differ between those with subsequent RM and a live birth [6.0% (0.7–12.5) vs 5.7% (0.4–14.4); $p = 0.8$].

For women with RIF, the median proportion of CD3⁺CD8⁺CD57⁺ cells did not differ between those with and without conception [3.3% (0.0–10.7) vs 3.9% (0.4–15.8); $p = 0.4$]. Similarly, the median proportion of CD3⁺CD8⁺CD57⁺ cells did not differ between women with a miscarriage and a live birth [2.3% (1.2–4.3) vs 3.3% (0.0–10.7); $p = 0.6$].

Meta-analysis

The literature review of 22 studies evaluating NK cells in RM and infertile populations is presented in Tables 3 and 4.

The literature search yielded 16 citations for the RM population (Chao et al. 1995; Emmer et al. 2000; Fukui et al. 2008; Ghafourian et al. 2014; Hosseini et al. 2014; Karami et al. 2012; King et al. 2010; Kuon et al. 2017; Michou et al. 2003; Ntrivalas et al. 2005; Prado-Drayer et al. 2008; Shakhari et al. 2003; Souza et al. 2002; Triggianese et al. 2016; Wang et al. 2008; Zhu et al. 2017). Only ten studies had relevant data and were included in the meta-analysis. The definition of RM was heterogeneous, with four studies including patients with ≥ 2 consecutive spontaneous miscarriages and seven including those with ≥ 3 consecutive spontaneous miscarriages. The NK percentage was defined as CD56⁺ cells in four studies, CD56⁺ or CD16⁺ cells in three and CD56⁺CD16⁺ cells in four. The CD56^{dim}CD16⁺ and CD56^{bright} sub-populations were evaluated in three and in two studies, respectively.

The meta-analysis of 11 studies (including our results) reporting the proportion of NK cells defined as CD56⁺ and/or CD16⁺ in women with RM showed increased proportion of NK cells compared with controls [mean difference 3.47 (95% confidence interval (CI) 2.94–4.00); $p < 0.001$] (Fig. 3). The heterogeneity between the studies was high (Fig. 4), with I^2 of 89% ($p < 0.0001$). The proportion of CD56⁺CD16⁺ NK cells was significantly higher for women with RM than healthy controls [mean difference 2.72 (95%

Table 2 Proportion of CD3⁻CD56⁺ NK cells and CD3⁺CD8⁺CD57⁺ T-LGLs and their sub-populations in women with RM and RIF

NK cell and T-LGL populations	RM or RIF <i>n</i> = 95	RM <i>n</i> = 54	RIF <i>n</i> = 41	Controls <i>n</i> = 20
Total NK cells: CD3 ⁻ CD56 ⁺ /CD45 ⁺	9.4 (2.5–31.6)	9.4 (2.5–31.6)	9.4 (4.3–29.3)	10.6 (3.4–20.2)
CD56 ^{bright} CD16 ⁻ /CD56 ⁺	7.6 (0.0–23.0)	6.7 (0.0–19.6)	8.1 (0.0–23.0)	5.8 (2.0–18.9)
CD56 ^{dim} CD16 ⁺ /CD56 ⁺	92.4 (77.0–100.0)	93.3 (80.4–100.0)	91.9 (77.0–100.0)	94.3 (81.1–98.0)
CD56 ^{dim} CD16 ⁺ CD57 ⁺ /CD56 ⁺	48.6 (17.7–85.0)	48.6 (17.7–85.0)	49.6 (18.2–80.9)	45.2 (28.2–77.2)
CD56 ^{dim} CD16 ⁺ CD57 ⁻ /CD56 ⁺	42.0 (13.2–73.5)	43.6 (13.2–68.3)	41.6 (15.0–73.5)	48.0 (18.9–65.2)
T-LGL: CD3 ⁺ CD8 ⁺ CD57 ⁺ /CD45 ⁺	4.4 (0.0–18.4)	5.4 (0.4–14.4)	4.3 (0.0–18.4)	3.8 (0.3–9.7)
CD3 ⁺ CD8 ⁺ CD57 ⁻ /CD45 ⁺	17.0 (0.0–28.5)	15.8 (6.2–25.5)*	17.6 (0.0–28.5)	18.9 (12.8–27.6)*

Results are shown as median (range) percentage among analysed cell populations as indicated

RM recurrent miscarriage, RIF repeated implantation failure, Dim diminished, NK natural killer cells, T-LGL T-cell large granular lymphocytes

* $p < 0.05$

Table 3 Literature review of studies analysing NK cells in women with RM

References	NK cells	RM			Healthy fertile controls	
		Type	<i>n</i>	%	<i>n</i>	%
Shakhar et al. (2003)	CD56 or CD16	≥ 3, unexplained	67	13.17 ± 0.93	13	8.6 ± 1.57
King et al. (2010)	CD56	≥ 3	104	11.4 ± 4.87	33	8.8 ± 5.37
	CD56 ^{dim} % of NK			94.7 ± 3.85		92.5 ± 6.41
Chao et al. (1995)	CD56 or CD16	≥ 3, unexplained	10	19.8 ± 12.6	21	13.5 ± 7.1
Emmer et al. (2000)	CD56	≥ 2	142	13.2 (10.4–16.0)	37	13.53 (10.8–16.3)
	CD56 ⁺ CD16 ⁺			11.6 (9.0–14.2)		12.0 (9.6–14.4)
Souza et al. (2002)	CD56 or CD16	–	9	169 cells (127–178)	9	230 cells (111–273)
Prado-Drayer et al. (2008)	CD56 ⁺ CD16 ⁺	≥ 2	18	13.9 ± 7.1	10	6.0 ± 2.9
	CD56 ^{dim} CD16 ⁺ % of lymphocytes			6.7 ± 5.9		0.5 ± 0.7
Wang et al. (2008)	CD56	≥ 3	85	20.9 ± 6.7	27	20.4 ± 6.3
	CD56 ⁺ CD16 ⁺ % of lymphocytes			16.5 ± 6.0		16.6 ± 6.0
Hosseini et al. (2014)	CD56 ⁺ CD16 ⁺ % of NK	≥ 2	15	46.0 ± 19.1	15	38.6 ± 19.2
Triggianese et al. (2016)	CD56 ⁺ CD16 ⁺	≥ 2	145	15.8 ± 6.4	45	11.2 ± 4.7
Zhu et al. (2017)	CD56 or CD16	≥ 3	31	13.0 ± 6.2	37	11.0 ± 4.8
	CD56 ^{bright} % of lymphocytes			0.71 ± 0.33		0.68 ± 0.51
	CD56 ^{dim} CD16 ⁺ % of lymphocytes			11.0 ± 5.8		8.6 ± 4.4
Kuon et al. (2017)	CD56 ⁺ CD16 ⁺	≥ 3	147	12.0 ± 4.9	42	10.6 ± 4.2
Ntrivalas et al. (2005)	CD56	≥ 3	15	7.09 ± 1.64	7	6.31 ± 1.7
	CD56 ^{dim} CD16 ⁺ % of lymphocytes			5.64 ± 1.9		5.37 ± 1.44
Fukui et al. (2008)	CD56	≥ 2	25	10.8 (9.33–16.10)	15	12.66 (11.8–15.87)
	CD56 ^{bright} % of lymphocytes			0.56 (0.43–0.69)		0.52 (0.38–0.61)
	CD56 ^{dim} % of lymphocytes			10.01 (9.33–16.10)		12.27 (10.86–15.25)
Michou et al. (2003)	CD56 or CD16	2–5	25	217 cells ± 138.8	11	131.0 ± 63.1
Karami et al. (2012)	CD56 ^{bright} % of lymphocytes	≥ 2	23	0.61 (0.1–1.5)	36	0.62 (0.12–0.92)
	CD56 ^{dim} % of lymphocytes			4.0 (8.29–23.81)		5.37 (2.17–7.82)
Ghafourian et al. (2014)	CD56	≥ 2, unexplained	23	13.1 (9.24–24.24)	36	5.98 (2.42–8.69)

Data are shown as median (range) or mean ± SD percentage

Dim diminished, *NK* natural killer cells, *RM* recurrent miscarriage

CI 1.72–3.71); $p < 0.001$], and the sub-population of NK cells characterised as CD56^{dim}CD16⁺ was higher [mean difference 1.30 (95% CI 0.26–2.35); $p = 0.01$]. The proportion of CD56^{bright} NK cells did not differ between the groups [mean difference 0.03 (95% CI –0.09 to 0.14); $p = 0.66$] (Fig. 3).

The literature search yielded 11 citations for the infertile population (Fornari et al. 2002; Fukui et al. 2008; Ghafourian et al. 2014; Karami et al. 2012; Mardanian et al. 2015; McGrath et al. 2009; Michou et al. 2003; Ntrivalas et al. 2005; Sacks et al. 2012; Santillán et al. 2015; Vujisić et al. 2004). Only five studies had relevant data and were included in the meta-analysis. One study included women with unexplained infertility; in one study RIF was defined as failure of ≥ 2 in vitro fertilisation treatments and in two studies as the failure of ≥ 3 embryo transfers; and one study did not specify the definition of implantation failure. The NK-cell populations were defined as CD56⁺ in four studies and CD56⁺ or CD16⁺ in another study. The meta-analysis

was not performed for NK sub-populations in this group of patients because of few available data. The proportion of peripheral blood NK cells was higher for women with RIF than controls [mean difference 1.64 (95% CI 0.82–2.45); $p < 0.001$] (Fig. 3). The heterogeneity between the different studies was high (Fig. 4), with I^2 of 95% ($p < 0.0001$).

Discussion

Repetitive early pregnancy failures involve an increasing number of couples, with no reason found in half of the cases. Some of the cases can be explained by chromosomal abnormalities in relation to advanced age of the woman. Nevertheless, the implantation and placentation processes can be compared to the mechanisms of allogeneic graft, which makes the theory of defective tolerance plausible. Immunological abnormalities are found in more than three quarters of endometrial biopsies of patients with RM and RIF but the

Table 4 Literature review of studies analysing NK cells in women with RIF

References	NK cells	RIF		Healthy fertile controls		
		Type	<i>n</i>	%	<i>n</i>	%
Ntrivalas et al. (2005)	CD56	≥ 3 ET	15	3.97 ± 0.56	7	6.31 ± 1.7
	CD56 ^{dim} CD16 ⁺ % of leukocytes			3.35 ± 0.59		5.37 ± 1.44
Fukui et al. (2008)	CD56	≥ 2 IVF with ≥ 4 ET	20	8.77 (7.23–13.06)	15	12.66 (11.8–15.87)
	CD56 ^{bright} % of leukocytes			0.37 (0.33–0.57)		0.52 (0.38–0.61)
	CD56 ^{dim} % of leukocytes			8.32 (6.87–13.75)		12.27 (10.86–15.25)
Michou et al. (2003)	CD56 or CD16	≥ 3 IVF	33	272.2 cells ± 115.7	11	131.0 ± 63.1
Karami et al. (2012)	CD56 ^{bright} % of leukocytes	≥ IVF	20	0.65 (0.35–0.95)	36	0.62 (0.12–0.92)
	CD56 ^{dim} % of leukocytes			14.08 (8.07–22)		5.37 (2.17–7.82)
Ghafourian et al. (2014)	CD56	≥ 2 IVF	20	14.01 (8.5–22.87)	36	5.98 (2.42–8.69)
Sacks et al. (2012)	CD56	≥ ET	171	11.3 ± 4.9	33	8.73 ± 5.3
	CD56 ^{dim} % of NK			94.46 ± 3.78		92.57 ± 6.34
Fornari et al. (2002)	CD56 or CD16	Unexplained infertility	18	428 cells ± 42	8	118 cells ± 24
McGrath et al. (2009)	CD56	Unexplained infertility	15	13.5 (8.2–19.6)	8	14.2 (4.9–20.9)
Mardanian et al. (2015)	CD56 ^{dim} CD16 ⁺ % of leukocytes	Infertility	34	13.62 ± 4.63	16	4.51 ± 0.98
	CD56 ^{bright} CD16 ⁺			0.77 ± 0.22		0.71 ± 0.28
Santillán et al. (2015)	CD56 or CD16	≥ 3 ET	30	13.4 ± 1.2	35	8.4 ± 0.7
Vujisić et al. (2004)	–	≥ 3 IVF	18	5.5 (3.2–7.8)	NA	7.7 (2.4–15.1)

Data are shown as median (range) or mean ± SD percentage

Dim diminished, *ET* embryo transfer, *IVF* in vitro fecundation, *NK* natural killer cells, *RIF* recurrent implantation failure, *NA* not accessible

biopsy is not easily available and is time-consuming (Lédée et al. 2016). Less invasive diagnostic tools such as blood immune analysis are needed to guide the management of unexplained infertility; among them, the proportion of NK cells and other cytotoxic cells can be reliable blood markers. Here, we found that NK cell and T-LGL proportions are not sufficient markers to presume an immune origin in women with RM and RIF. In this homogeneous series of patients without any aetiological explanation for pregnancy failure despite extensive biological exploration, the NK-cell proportion did not differ from that in healthy controls.

Our observations support previous results for RM patients (Chao et al. 1995; Ntrivalas et al. 2005; Wang et al. 2008; Zhu et al. 2017) and an infertile population (McGrath et al. 2009). However, several studies reported an increased NK-cell proportion in RM patients (King et al. 2010; Ghafourian et al. 2014; Prado-Drayer et al. 2008; Shakhar et al. 2003; Triggianese et al. 2016) and in infertile populations (Ghafourian et al. 2014; Ntrivalas et al. 2005; Santillán et al. 2015), whereas one study (Sacks et al. 2012) found a decreased proportion of NK cells in an infertile population compared with the control group. The apparent discrepancies in the results can be explained by the non-consensual definition of NK cells in those studies. Moreover, RM and RIF definitions vary according to studies: some studies included patients with two recurrent miscarriages, not consecutive miscarriages and even not unexplained miscarriages. Another explanation could be a monthly variation of immune blood

cells within the menstrual regulation. Indeed, endometrial immune-cell concentrations fluctuate during the menstrual cycle under the action of sex steroid hormones, and their proliferation and activation depend on locally secreted factors (Wira et al. 2015). For infertile women, McGrath et al. (2009) did not observe a difference in the peripheral blood NK population when the phase of menstrual cycle was ignored. However, during the secretory phase, the authors observed a higher proportion of circulating NK cells in infertile women. Prado-Drayer et al. (2008) evaluated the proportion of NK cells during the secretory phase (D17–D26 of the cycle) and found an increased proportion in the RM population. The daily fluctuations of peripheral blood NK concentrations have also been reported (Petitto et al. 1992). Moreover, the time interval between the last abortion or implantation failure and blood analysis might have influenced NK peripheral blood results.

Furthermore, the role of peripheral blood and endometrial lymphocytes is distinct. The function of blood lymphocytes is mainly connected to the immune defence response, and their cytotoxic activity is regulated by many extrinsic and intrinsic factors, such as infection, anxiety and stress (Benschop et al. 1998).

The production of peripheral blood and endometrial immune cells is heterogeneous. NK cells in peripheral organs might originate from hematopoietic stem cells present in target organs, whereas circulating blood cells originate mostly from the bone marrow (Daussy et al. 2014).




Fig. 3 Meta-analysis of the literature studies of NK cell percentages in women with RM and RIF and healthy fertile controls, including our data. Total NK cells (a), CD56⁺CD16⁺ NK cells (b), CD56^{dim}CD16⁺ NK cell sub-population (c) and CD56^{bright} NK cell

sub-population (d) in RM women vs healthy fertile controls and total NK cells in infertile women vs healthy controls (e). Data are mean ± SD proportion of total leukocytes




Fig. 4 Forest plots showing the heterogeneity of literature studies of NK-cell proportions in women with RM and RIF and healthy controls, including our data. Total NK cells (**a**), CD56⁺CD16⁺ NK cells (**b**), CD56^{dim}CD16⁺ NK cell sub-population (**c**) and CD56^{bright}

NK cell sub-population (**d**) in women with RM vs healthy controls and total NK cells in infertile women vs healthy controls (**e**). Data are mean \pm SD proportion of total leukocytes

Moreover, the phenotypes of peripheral blood and endometrial NK cells differ. More than 90% of the endometrial NK population is characterised by the immature phenotype, CD56^{bright}CD16⁻, whereas the most dominant sub-population in the blood is the mature phenotype, CD56^{dim}CD16⁺ (Mekinian et al. 2016; Moffett-King 2002). Therefore, extrapolating the results of peripheral blood immune cell analysis is difficult for predicting the immunological status of the endometrium.

Our meta-analysis, similar to the previous meta-analysis (Seshadri and Sunkara 2014), showed increased NK-cell proportion in women with RM and with infertility; but in

the high level of heterogeneity, various study population selections and NK-cell definitions preclude from definitely concluding on the value of NK-cell analysis in women with RM and RIF. In particular, two studies (Ghafourian et al. 2014; Prado-Drayer et al. 2008) reported remarkably low proportions of NK cells in healthy controls, which strongly influence the results of the meta-analysis.

Women with high NK-cell activity in the preconception period may have low rates of subsequent pregnancy success (Aoki et al. 1995). In the present study, the proportions of NK cells and T-LGLs did not differ between

women with a consecutive miscarriage and live birth or with implantation failure and successful pregnancy.

Another interesting point is the value of peripheral blood NK-cell proportions to monitor the immunomodulatory treatment. Steroid treatment of patients with unexplained RM and RIF presenting high preconception number of endometrial NK cells significantly reduces the number (Quenby et al. 2005). Progesterone promotes the anti-cytotoxic cytokine profile induced by the NK-cell synthesis of progesterone-induced blocking factor (Raghupathy et al. 2009). Intravenous immunoglobulin administration decreases peripheral blood proportion of NK cells (Moraru et al. 2012), with discordant effects on the chances of pregnancy (Christiansen et al. 2015; Moraru et al. 2012; Stephenson et al. 2010). Intralipid administration modifies the peripheral blood NK-cell activity in vitro (Roussev et al. 2007) and in vivo (Roussev et al. 2008). Even if steroids and intralipid treatments were used in our patients, no difference was shown between patients with and without a live birth; but more specific studies are needed.

The major strength of the study is the large number of patients included in the analysis from a homogeneous population of women with RM and RIF. The patients were recruited in three strictly collaborating departments with a pluridisciplinary consultation meeting and an exhaustive exploration of RM and RIF. Recurrent miscarriage and repeated implantation failure populations were considered separately to limit the bias related to factors specific to each condition. The blood samples were analysed without consideration of menstrual cycle phase and the long recruitment period, which could explain some variation in NK-cell proportions. Only relative proportions of NK and T-LGL cells were analysed, which presents a limitation for the meta-analysis.

In conclusion, peripheral blood CD3⁻CD56⁺ and CD8⁺CD57⁺ cell levels are not associated with implantation failure or miscarriage and should not be recommended indicators for the management of RM and RIF. Further prospective large studies are needed to develop a reliable peripheral blood marker of the immune deregulation potentially involved in RIF and RM.

Acknowledgements We thank Laura Smales for the English corrections.

Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent Informed consent was obtained from all individual participants included in the study.

References

- Aoki K, Kajjura S, Matsumoto Y et al (1995) Preconceptional natural-killer-cell activity as a predictor of miscarriage. *Lancet* 345:1340–1342
- Benschop RJ, Geenen R, Mills PJ et al (1998) Cardiovascular and immune responses to acute psychological stress in young and old women: a meta-analysis. *Psychosom Med* 60:290–296
- Bero L, Rennie D (1995) The Cochrane Collaboration. Preparing, maintaining, and disseminating systematic reviews of the effects of health care. *JAMA* 274:1935–1938
- Chao KH, Yang YS, Ho HN et al (1995) Decidual natural killer cytotoxicity decreased in normal pregnancy but not in anembryonic pregnancy and recurrent spontaneous abortion. *Am J Reprod Immunol* 34:274–280
- Chen X, Mariee N, Jiang L et al (2017) Measurement of uterine natural killer cell percentage in the periimplantation endometrium from fertile women and women with recurrent reproductive failure: establishment of a reference range. *Am J Obstet Gynecol* 217:680.e1–680.e6
- Christiansen OB, Larsen EC, Egerup P et al (2015) Intravenous immunoglobulin treatment for secondary recurrent miscarriage: a randomised, double-blind, placebo-controlled trial. *BJOG* 122:500–508
- Daussy C, Faure F, Mayol K et al (2014) T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow. *J Exp Med* 211:563–577
- Dolstra H, Preijers F, Van de Wiel-van Kemenade E et al (1995) Expansion of CD8⁺CD57⁺T cells after allogeneic BMT is related with a low incidence of relapse and with cytomegalovirus infection. *Br J Haematol* 90:300–307
- Emmer PM, Nelen WL, Steegers EA et al (2000) Peripheral natural killer cytotoxicity and CD56(pos)CD16(pos) cells increase during early pregnancy in women with a history of recurrent spontaneous abortion. *Hum Reprod* 15:1163–1169
- Fornari MC, Sarto A, Berardi VE et al (2002) Effect of ovarian hyperstimulation on blood lymphocyte subpopulations, cytokines, leptin and nitrite among patients with unexplained infertility. *Am J Reprod Immunol* 48:394–403
- Fukui A, Kwak-Kim J, Ntrivalas E et al (2008) Intracellular cytokine expression of peripheral blood natural killer cell subsets in women with recurrent spontaneous abortions and implantation failures. *Fertil Steril* 89:157–165
- Ghafourian M, Karami N, Khodadadi A et al (2014) Increase of CD69, CD161 and CD94 on NK cells in women with recurrent spontaneous abortion and in vitro fertilization failure. *Iran J Immunol* 11:84–96
- Gill H, Ip AH, Leung R et al (2012) Indolent T-cell large granular lymphocyte leukaemia after haematopoietic SCT: a clinicopathologic and molecular analysis. *Bone Marrow Transplant* 47:952–956
- Hosseini S, Zarnani AH, Asgarian-Omran H et al (2014) Comparative analysis of NK cell subsets in menstrual and peripheral blood of patients with unexplained recurrent spontaneous abortion and fertile subjects. *J Reprod Immunol* 103:9–17

- Karami N, Boroujerdnia MG, Nikbakht R et al (2012) Enhancement of peripheral blood CD56(dim) cell and NK cell cytotoxicity in women with recurrent spontaneous abortion or in vitro fertilization failure. *J Reprod Immunol* 95:87–92
- King K, Smith S, Chapman M et al (2010) Detailed analysis of peripheral blood natural killer (NK) cells in women with recurrent miscarriage. *Hum Reprod* 25:52–58
- Kuon RJ, Vomstein K, Weber M et al (2017) The “killer cell story” in recurrent miscarriage: association between activated peripheral lymphocytes and uterine natural killer cells. *J Reprod Immunol* 119:9–14
- Lamy T, Moignet A, Loughran TP (2017) LGL leukemia: from pathogenesis to treatment. *Blood* 129:1082–1094
- Lédée N, Petitbarat M, Chevrier L et al (2016) The uterine immune profile may help women with repeated unexplained embryo implantation failure after in vitro fertilization. *Am J Reprod Immunol* 75:388–401
- Manaster I, Mandelboim O (2008) The unique properties of human NK cells in the uterine mucosa. *Placenta* 29(Suppl A):S60–S66
- Mardanian F, Kazeroonzadeh M, Rashidi B (2015) Evaluation of CD56(dim) and CD56(bright) natural killer cells in peripheral blood of women with IVF failures. *Iran J Reprod Med* 13:577–582
- Matsuda K, Taoka K, Jona M et al (2017) Clinical features of hematological disorders with increased large granular lymphocytes (LGLs): a retrospective study. *Ann Hematol* 96:2113–2115
- McGrath E, Ryan EJ, Lynch L et al (2009) Changes in endometrial natural killer cell expression of CD94, CD158a and CD158b are associated with infertility. *Am J Reprod Immunol* 61:265–276
- Mekinian A, Cohen J, Alijotas-Reig J et al (2016) Unexplained recurrent miscarriage and recurrent implantation failure: is there a place for immunomodulation? *Am J Reprod Immunol* 76:8–28
- Michou VI, Kanavaros P, Athanassiou V et al (2003) Fraction of the peripheral blood concentration of CD56+/CD16-/CD3- cells in total natural killer cells as an indication of fertility and infertility. *Fertil Steril* 80(Suppl 2):691–697
- Moffett-King A (2002) Natural killer cells and pregnancy. *Nat Rev Immunol* 2:656–663
- Mohty M, Faucher C, Gaugler B et al (2001) Large granular lymphocytes (LGL) following non-myeloablative allogeneic bone marrow transplantation: a case report. *Bone Marrow Transplant* 28:1157–1160
- Mohty M, Faucher C, Vey N et al (2002) Features of large granular lymphocytes (LGL) expansion following allogeneic stem cell transplantation: a long-term analysis. *Leukemia* 16:2129–2133
- Moraru M, Carbone J, Alecsandru D et al (2012) Intravenous immunoglobulin treatment increased live birth rate in a Spanish cohort of women with recurrent reproductive failure and expanded CD56(+) cells. *Am J Reprod Immunol* 68:75–84
- Ntrivalas EI, Bowser CR, Kwak-Kim J et al (2005) Expression of killer immunoglobulin-like receptors on peripheral blood NK cell subsets of women with recurrent spontaneous abortions or implantation failures. *Am J Reprod Immunol* 53:215–221
- Petitto JM, Folds JD, Ozer H et al (1992) Abnormal diurnal variation in circulating natural killer cell phenotypes and cytotoxic activity in major depression. *Am J Psychiatry* 149:694–696
- Prado-Druyer A, Teppa J, Sánchez P et al (2008) Immunophenotype of peripheral T lymphocytes, NK cells and expression of CD69 activation marker in patients with recurrent spontaneous abortions, during the mid-luteal phase. *Am J Reprod Immunol* 60:66–74
- Quenby S, Kalumbi C, Bates M et al (2005) Prednisolone reduces pre-conceptual endometrial natural killer cells in women with recurrent miscarriage. *Fertil Steril* 84:980–984
- Raghupathy R, Al-Mutawa E, Al-Azemi M et al (2009) Progesterone-induced blocking factor (PIBF) modulates cytokine production by lymphocytes from women with recurrent miscarriage or preterm delivery. *J Reprod Immunol* 80:91–99
- Roussev RG, Ng SC, Coulam CB (2007) Natural killer cell functional activity suppression by intravenous immunoglobulin, intralipid and soluble human leukocyte antigen-G. *Am J Reprod Immunol* 57:262–269
- Roussev RG, Acacio B, Ng SC et al (2008) Duration of intralipid’s suppressive effect on NK cell’s functional activity. *Am J Reprod Immunol* 60:258–263
- Sacks G, Yang Y, Gowen E et al (2012) Detailed analysis of peripheral blood natural killer cells in women with repeated IVF failure. *Am J Reprod Immunol* 67:434–442
- Santillán I, Lozano I, Illán J et al (2015) Where and when should natural killer cells be tested in women with repeated implantation failure? *J Reprod Immunol* 108:142–148
- Seshadri S, Sunkara SK (2014) Natural killer cells in female infertility and recurrent miscarriage: a systematic review and meta-analysis. *Hum Reprod Update* 20:429–438
- Shakhar K, Ben-Eliyahu S, Loewenthal R et al (2003) Differences in number and activity of peripheral natural killer cells in primary versus secondary recurrent miscarriage. *Fertil Steril* 80:368–375
- Shepard TH, Fantel AG (1979) Embryonic and early fetal loss. *Clin Perinatol* 6:219–243
- Southcombe JH, Mounce G, McGee K et al (2017) An altered endometrial CD8 tissue resident memory T cell population in recurrent miscarriage. *Sci Rep* 7:41335
- Souza SS, Ferriani RA, Santos CM et al (2002) Immunological evaluation of patients with recurrent abortion. *J Reprod Immunol* 56:111–121
- Stephenson MD, Kutteh WH, Purkiss S et al (2010) Intravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multicentered randomized placebo-controlled trial. *Hum Reprod* 25:2203–2209
- Strioga M, Pasukoniene V, Characiejus D (2011) CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease. *Immunology* 134:17–32
- Thornhill AR, deDie-Smulders CE, Geraedts JP et al (2005) ESHRE PGD Consortium “Best practice guidelines for clinical preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS)”. *Hum Reprod* 20:35–48
- Triggianese P, Perricone C, Conigliaro P et al (2016) Peripheral blood natural killer cells and mild thyroid abnormalities in women with reproductive failure. *Int J Immunopathol Pharmacol* 29:65–75
- Vujisić S, Lepez SZ, Aksamija A et al (2004) B- and T-cells in the follicular fluid and peripheral blood of patients undergoing IVF/ET procedures. *Am J Reprod Immunol* 52:379–385
- Wang EC, Lehner PJ, Graham S et al (1994) CD8high (CD57+) T cells in normal, healthy individuals specifically suppress the generation of cytotoxic T lymphocytes to Epstein–Barr virus-transformed B cell lines. *Eur J Immunol* 24:2903–2909
- Wang Q, Li TC, Wu YP et al (2008) Reappraisal of peripheral NK cells in women with recurrent miscarriage. *Reprod Biomed Online* 17:814–819
- Wira CR, Rodriguez-Garcia M, Patel MV (2015) The role of sex hormones in immune protection of the female reproductive tract. *Nat Rev Immunol* 15:217–230
- Zhang X, Sokol L, Bennett JM et al (2016) T-cell large granular lymphocyte proliferation in myelodysplastic syndromes: clinicopathological features and prognostic significance. *Leuk Res* 43:18–23
- Zhu L, Aly M, Wang H et al (2017) Decreased NK cell immunity in kidney transplant recipients late post-transplant and increased NK-cell immunity in patients with recurrent miscarriage. *PLoS One* 12:e0186349

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.